as 07-04-2025 12:33pm EST
Glaukos Corp is an ophthalmic pharmaceutical and medical technology company focused on developing novel, dropless therapies and commercializing associated products for the treatment of glaucoma, corneal disorders, and retinal diseases. It has commenced commercialization activities for iDose TR, a first-of-its-kind, long-duration, intracameral procedural pharmaceutical implant designed to continuously deliver glaucoma drug therapy inside the eye for extended periods of time. The company also offer commercially a proprietary bio-activated pharmaceutical therapy for the treatment of a rare corneal disorder, keratoconus. It has three primary commercialized micro-scale surgical device products designed to treat glaucoma: the iStent, the iStent inject W, and the iStent infinite.
Founded: | 1998 | Country: | United States |
Employees: | N/A | City: | ALISO VIEJO |
Market Cap: | 5.8B | IPO Year: | 2015 |
Target Price: | $135.15 | AVG Volume (30 days): | 903.0K |
Analyst Decision: | Strong Buy | Number of Analysts: | 13 |
Dividend Yield: | N/A | Dividend Payout Frequency: | N/A |
EPS: | -2.27 | EPS Growth: | N/A |
52 Week Low/High: | $77.10 - $163.71 | Next Earning Date: | 07-30-2025 |
Revenue: | $404,523,000 | Revenue Growth: | 23.92% |
Revenue Growth (this year): | 27.88% | Revenue Growth (next year): | 27.60% |
GKOS Breaking Stock News: Dive into GKOS Ticker-Specific Updates for Smart Investing
Medical Device Network
8 days ago
MT Newswires
10 days ago
Business Wire
10 days ago
PR Newswire
10 days ago
Business Wire
11 days ago
Argus Research
11 days ago
Zacks
19 days ago
Zacks
24 days ago
The information presented on this page, "GKOS Glaukos Corporation - Stocks Price | History | Analysis", including historical data, forecasts, news, insider information, and predictions, is provided for educational purposes only. It should not be considered as financial advice or a recommendation to buy or sell any securities. Decisions regarding investments should be made only after careful consideration and consultation with a qualified financial advisor. We do not endorse or guarantee the accuracy or reliability of the information provided, and we disclaim any liability for financial losses incurred as a result of decisions made based on the information presented.